勵晶太平洋：2025中期報告.pdf

1、2Performance Overview業績概覽4Managements Discussion and Analysis of the Groups Performance管理層對本集團業績之 討論及分析13Condensed Consolidated Statement of Profit or Loss and Other Comprehensive Income簡明綜合損益及 其他全面收益表15Condensed Consolidated Statement of Financial Position簡明綜合財務狀況表17Condensed Consolidated Statement

2、 of Changes in Equity簡明綜合權益變動表18Condensed Consolidated Statement of Cash Flows簡明綜合現金流量表20Notes to the Condensed Consolidated Financial Statements簡明綜合財務報表附註57Trading Record Over Last Five Years過去五年營業記錄58Other Information其他資料70Definitions釋義76Corporate Information公司資料CONTENTS目錄REGENT PACIFIC GROUP LIMI

3、TED 勵晶太平洋集團有限公司2PERFORMANCE OVERVIEW業績概覽 A summary of the financial performance and other notable events for the six months ended 30 June 2025 include:A reduced loss attributable to shareholders of the Company of approximately US$2.22 million,which was mainly attributable to the Groups operating and

4、 R&D expenses of approximately US$2.25 million.In respect of the progress being made with Senstend in the PRC,the main objective remains for Wanbang Biopharmaceutical to obtain marketing approval by the end of 2025,with first commercial launch projected to start in Q1 2026.If the NMPA grants an impo

5、rt licence for Senstend,US$5 million(before deduction of PRC withholding tax)shall be payable to the Group from Wanbang Biopharmaceutical.In addition,upon first commercial sale of Senstend in China,US$2 million(before deduction of PRC withholding tax)shall be payable to the Group from Wanbang Biopha

6、rmaceutical.In respect of the progress being made with Fortacin in the US,the Company has evaluated two proposals from reputable clinical research organisations(“CRO”)in respect of undertaking the Phase 3 clinical studies in the US and is in discussions with a number of pharmaceutical companies for“